Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 14 - What They Never Told You

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

Tribune News Service

3 Large-Cap Stocks to Add to Your Portfolio Now

The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharmaceutical giant Eli Lilly & Co apologises after fake Twitter account says insulin is free as Elon Musk rolls back verification

The incident is among a wave of impersonations that prompted Twitter to make its relaunched premium service unavailable.

ABC News

No, insulin is not free: Eli Lilly is the latest high-profile casualty of Elon Musk’s Twitter verification mess

Eli Lilly shares fell after pranksters using Twitter Blue impersonated it and made a surprising claim—and this might be just the beginning.

Fortune

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

The Independent UK

These companies claim to support abortion rights. They are backing anti-abortion Republicans

An analysis of major companies’ donations, including Meta and Amazon, reveals donations to candidates calling for banning the procedure

The Guardian - US

Read news from The Economist, FT, and more,
with one subscription

New generation of weight loss medications offer promise — but at a price

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

Tribune News Service

3 Names It Wouldn’t Hurt to Stock up On

Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…

StockNews.com

Elon Musk Twitter Case Deposition Delayed, FTX US Goes Shopping, Spotify's Analyst Sees Audiobooks Immaterial: Top Financial Media Stories Tuesday, Sept. 27

Bloomberg

Benzinga

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Chicago Sun-Times

Eli Lilly says Indiana abortion law forces hiring out-of-state

Eli Lilly & Co., one of Indiana’s largest employers, said the state’s freshly passed restrictions on abortion would force the drugmaker to “plan for more employment growth outside our home state.”

Tribune News Service

Major Indiana employer speaks out on state’s near-total abortion ban and vows to look outside state for ‘employment growth’

Pharmaceutical giant Eli Lilly is headquartered in Indianapolis and employs more than 10,000 people in the state

The Independent UK

Kerry Katona wants daughter Lily, 19, to have baby as she's worried about dying

Kerry says her “health anxiety” causes her to constantly worry about dying young and she would love for her teenage daughter Lilly to have a child of her own

Daily Mirror

Get all your
news in one place.

100's of premium titles.
One news app.

Los Angeles Times

Michael Hiltzik: As professionals flee antiabortion policies, red states face a brain drain

A few days ago, a university headhunter reached out to Elizabeth T. Jacobs, a professor of epidemiology at the University of Arizona, to gauge her interest in moving to a leading university in Texas.

Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Benzinga

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

Benzinga

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Executives Sell Over $100M Of 4 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Benzinga

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Benzinga

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Benzinga

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Tribune News Service

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations